Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinod Rustgi

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Case Reports in Hepatology|November 30, 2019
Hepatic Silicone Granulomas Secondary to Ruptured Breast Implants: A Report of Two CasesRachel Hudacko, Kapil Anand, Ronald Gordon, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 21, 2010
Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapyVinod Rustgi, David R Nelson, Vijayan Balan, et al.
Digestive Diseases and Sciences|March 17, 2021
Safety and Efficacy of Thrombin for Bleeding Gastric Varices: A Systematic Review and Meta-AnalysisAbhishek Bhurwal, Michael Makar, Anish Patel, et al.
Gastro Hep Advances|August 12, 2024
The Epidemiology, Transmission, Genotypes, Replication, Serologic and Nucleic Acid Testing, Immunotolerance, and Reactivation of Hepatitis B VirusAnkoor Patel, Zahra Dossaji, Kapil Gupta, et al.
The American Journal of Gastroenterology|April 6, 2016
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
The American Journal of Gastroenterology|July 1, 2016
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
Hepatology (Baltimore, Md.)|May 30, 2003
A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapyPaul J Pockros, Keyvr Patel, Christopher O'Brien, et al.
Journal of Hepatology|April 4, 2015
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphineJacob Lalezari, J Greg Sullivan, Peter Varunok, et al.
Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.
The Lancet. Infectious Diseases|July 19, 2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyAnita Kohli, Rama Kapoor, Zayani Sims, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Case Reports in Hepatology|November 30, 2019
Hepatic Silicone Granulomas Secondary to Ruptured Breast Implants: A Report of Two CasesRachel Hudacko, Kapil Anand, Ronald Gordon, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 21, 2010
Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapyVinod Rustgi, David R Nelson, Vijayan Balan, et al.
Digestive Diseases and Sciences|March 17, 2021
Safety and Efficacy of Thrombin for Bleeding Gastric Varices: A Systematic Review and Meta-AnalysisAbhishek Bhurwal, Michael Makar, Anish Patel, et al.
Gastro Hep Advances|August 12, 2024
The Epidemiology, Transmission, Genotypes, Replication, Serologic and Nucleic Acid Testing, Immunotolerance, and Reactivation of Hepatitis B VirusAnkoor Patel, Zahra Dossaji, Kapil Gupta, et al.
The American Journal of Gastroenterology|April 6, 2016
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
The American Journal of Gastroenterology|July 1, 2016
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsMitchell L Shiffman, Vinod Rustgi, Michael Bennett, et al.
Hepatology (Baltimore, Md.)|May 30, 2003
A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapyPaul J Pockros, Keyvr Patel, Christopher O'Brien, et al.
Journal of Hepatology|April 4, 2015
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphineJacob Lalezari, J Greg Sullivan, Peter Varunok, et al.
Antiviral Therapy|August 28, 2015
Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)Christophe Hézode, Laurent Alric, Ashley Brown, et al.
The Lancet. Infectious Diseases|July 19, 2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyAnita Kohli, Rama Kapoor, Zayani Sims, et al.
Pageof 5